Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Investments (2016 - 2019)

Historic Long-Term Investments for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q4 2019 value amounting to $19.0 million.

  • Lineage Cell Therapeutics' Long-Term Investments fell 640.39% to $19.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $19.0 million, marking a year-over-year decrease of 640.39%. This contributed to the annual value of $19.0 million for FY2019, which is 640.39% down from last year.
  • Lineage Cell Therapeutics' Long-Term Investments amounted to $19.0 million in Q4 2019, which was down 640.39% from $17.7 million recorded in Q3 2019.
  • In the past 5 years, Lineage Cell Therapeutics' Long-Term Investments registered a high of $110.8 million during Q3 2017, and its lowest value of $4.4 million during Q1 2016.
  • Over the past 5 years, Lineage Cell Therapeutics' median Long-Term Investments value was $43.2 million (recorded in 2018), while the average stood at $50.6 million.
  • In the last 5 years, Lineage Cell Therapeutics' Long-Term Investments soared by 204170.41% in 2016 and then tumbled by 7024.99% in 2018.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Long-Term Investments stood at $4.7 million in 2015, then surged by 2041.7% to $100.0 million in 2016, then plummeted by 31.79% to $68.2 million in 2017, then tumbled by 70.25% to $20.3 million in 2018, then fell by 6.4% to $19.0 million in 2019.
  • Its Long-Term Investments was $19.0 million in Q4 2019, compared to $17.7 million in Q3 2019 and $36.5 million in Q2 2019.